H 89 2HCl: Potent and Selective PKA Inhibitor for cAMP Pathway Research

Executive Summary: H 89 2HCl is a highly selective inhibitor of protein kinase A (PKA), exhibiting a Ki of 48 nM in cell-free conditions and over 500-fold selectivity against non-PKA kinases (APExBIO, product page). This compound acts by blocking cAMP-dependent protein phosphorylation without altering intracellular cAMP levels (Wang et al., DOI:10.1016/j.cellsig.2020.109847). H 89 2HCl suppresses forskolin-induced neurite outgrowth and histone IIb phosphorylation in PC12D cells, serving as a model for cAMP/PKA signaling modulation. The compound is highly soluble in DMSO (≥51.9 mg/mL), but insoluble in water and ethanol, and is recommended for storage as a solid at –20°C. These features make H 89 2HCl a preferred reagent for dissecting cAMP/PKA signaling in neurobiology, cancer, and bone research applications.

Biological Rationale

Protein kinase A (PKA) is a key effector in the cAMP-dependent signaling pathway, regulating numerous cellular processes including gene expression, metabolism, cell differentiation, and neuronal plasticity. Dysregulation of PKA activity has been implicated in cancer, neurodegenerative diseases, and metabolic disorders (Wang et al., 2021). Pharmacological inhibition of PKA is essential for mechanistic studies aiming to delineate the roles of cAMP/PKA signaling in these pathologies. H 89 2HCl, supplied by APExBIO, provides a highly selective approach for inhibiting PKA, enabling researchers to selectively probe cAMP/PKA pathway function without broad off-target effects (APExBIO).

Mechanism of Action of H 89 2HCl

H 89 2HCl, chemically (E)-N-(2-((3-(4-bromophenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide dihydrochloride, acts as an ATP-competitive inhibitor at the catalytic subunit of PKA. It exhibits a Ki of 48 nM in cell-free assays and demonstrates approximately 10-fold selectivity for PKA over PKG, and >500-fold selectivity over kinases such as PKC, MLCK, CaMKII, and casein kinase I/II (APExBIO). H 89 2HCl also inhibits S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b, but with higher IC50 values (80–2800 nM), minimizing unintended pathway modulation at concentrations optimized for PKA inhibition. Mechanistically, H 89 2HCl prevents cAMP-activated protein phosphorylation but does not alter intracellular cAMP concentrations. In PC12D pheochromocytoma cells, this leads to a dose-dependent suppression of forskolin-induced neurite outgrowth and histone IIb phosphorylation (Wang et al., 2021).

Evidence & Benchmarks

• H 89 2HCl inhibits PKA activity with a Ki of 48 nM in cell-free kinase assays (APExBIO).
• The compound displays >500-fold selectivity for PKA over kinases such as PKC, MLCK, CaMKII, and casein kinase I/II (APExBIO).
• In animal models, H 89 2HCl modulates CREB phosphorylation, implicating cAMP/PKA signaling in osteoclast differentiation (Wang et al., DOI:10.1016/j.cellsig.2020.109847).
• H 89 2HCl does not reduce intracellular cAMP levels, as validated in PC12D cells, confirming its mechanism is downstream of cAMP generation (Wang et al., 2021).
• Solubility is ≥51.9 mg/mL in DMSO at room temperature; compound is insoluble in water and ethanol (APExBIO).

For further reading, the article H 89 2HCl: Potent and Selective PKA Inhibitor for cAMP Pa... gives an overview of molecular action and applications; this current article details recent evidence and technical storage parameters not covered in that summary.

Applications, Limits & Misconceptions

H 89 2HCl is widely used in cellular and animal models to dissect the roles of cAMP/PKA signaling in neurobiology, cancer, and bone metabolism. Its high selectivity allows precise inhibition in cell viability, proliferation, differentiation, and signaling assays. For example, H 89 2HCl was key in demonstrating that dopamine suppresses osteoclast differentiation via reduced CREB phosphorylation, confirming the centrality of the cAMP/PKA pathway in bone remodeling (Wang et al., 2021).

See also H 89 2HCl (SKU B2190): Data-Driven PKA Inhibition for Rel... for assay optimization guidance; this article updates key selectivity benchmarks and scenario use-cases.

Common Pitfalls or Misconceptions

• H 89 2HCl is not a pan-kinase inhibitor; it will not broadly inhibit all serine/threonine kinases.
• At high concentrations (>10 μM), off-target inhibition of kinases like S6K1 and MSK1 may occur; dose titration is required for pathway specificity (APExBIO).
• H 89 2HCl does not reduce cellular cAMP production; effects on cAMP levels must be separately assayed (Wang et al., 2021).
• The compound is insoluble in water and ethanol; improper solvent use leads to precipitation and unreliable results.
• Intended for research use only; not for diagnostic or clinical application (APExBIO).

For deeper workflow integration, see H 89 2HCl (SKU B2190): Reliable PKA Inhibition for Cell A..., which focuses on reproducibility and best practices; the current article includes recent solubility and selectivity data.

Workflow Integration & Parameters

• Preparation: Dissolve H 89 2HCl in DMSO (≥51.9 mg/mL). Avoid water or ethanol to prevent precipitation (APExBIO).
• Storage: Store solid at –20°C. Prepare solutions immediately prior to use to minimize degradation.
• Assay Concentrations: Typical working range is 0.5–10 μM for PKA inhibition; titrate to minimize off-target effects.
• Controls: Include vehicle (DMSO) controls in all experiments.
• Validation: Confirm pathway inhibition by measuring substrate phosphorylation (e.g., CREB, histone IIb).

Conclusion & Outlook

H 89 2HCl, available from APExBIO, is a highly selective and potent inhibitor of protein kinase A, essential for mechanistic studies of cAMP/PKA signaling. Its well-characterized selectivity, solubility, and mechanism of action enable reproducible results in diverse experimental systems. As research advances in neurobiology, oncology, and bone metabolism, H 89 2HCl will remain a core tool for dissecting kinase-mediated signaling pathways. For detailed protocols and the latest product data, refer to the H 89 2HCl product page.